Amgen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Everest Financial Group LLC Takes $530,000 Position in Amgen Inc. $AMGN

AI-generated analysis

📈 Everest Financial Group LLC initiated a new position in Amgen Inc. by buying 1,505 shares valued at roughly $530,000 during the first quarter.

📊 Anfield Capital Management LLC significantly increased its holdings by 1,000% to own 77 shares worth $25,000 in the fourth quarter.

💰 Amgen reported quarterly revenue of $8.62 billion, which was up 5.8% year-over-year compared to analyst expectations of $8.58 billion.

📉 The company beat earnings estimates with $5.15 EPS versus a consensus of $4.77, achieving a net margin of 20.96%.

🎯 Amgen provided full-year 2026 guidance for EPS between $21.70 and $23.10, slightly below the average analyst target of $22.31.

📉 Wall Street Zen downgraded Amgen from a buy to a hold rating in a report dated June 27th.

📉 Morgan Stanley decreased its price target from $340.00 to $333.00 and assigned an equal weight rating on July 8th.

📈 Guggenheim raised its price target to $343.00 but maintained a neutral rating in a report from July 13th.

👤 Senior Vice President Nancy A. Grygiel sold 1,237 shares for approximately $400,454 on May 4th, reducing her position by 15%.

🏛️ Institutional ownership stands at 76.50%, with insider ownership currently at 0.85% of the total stock.

Bullish Signals
  • Amgen beat quarterly earnings expectations significantly, reporting $5.15 EPS compared to the consensus estimate of $4.77.
  • The company achieved a robust net margin of 20.96% and a high return on equity of 137.41% for the quarter.
  • Revenue grew by 5.8% year-over-year to reach $8.62 billion, exceeding analyst forecasts of $8.58 billion.
  • Everest Financial Group LLC initiated a new position in the stock, indicating institutional interest.
  • Anfield Capital Management LLC increased its holdings by 1,000%, signaling strong confidence from this specific hedge fund.
Risk Factors
  • Wall Street Zen downgraded Amgen from a buy to a hold rating, reflecting some caution among analysts.
  • Morgan Stanley lowered its price target from $340.00 to $333.00 and assigned an equal weight rating.
  • The consensus analyst price target of $356.62 is below the recent high targets mentioned by other firms like Guggenheim.
  • Senior Vice President Nancy A. Grygiel sold a significant portion of her holdings, reducing her position by 15%.
Full Analysis
Everest Financial Group LLC established a new position in Amgen Inc. (NASDAQ: AMGN) during the first quarter, purchasing 1,505 shares valued at approximately $530,000 per its latest Form 13F filing. Several other institutional investors also adjusted their holdings recently, including Anfield Capital Management LLC which increased its stake by 1,000% to own 77 shares worth $25,000, and Dogwood Wealth Management LLC which raised its position by 275% to hold 75 shares valued at $25,000. Amgen reported strong quarterly financial results announced on April 30th, with revenue of $8.62 billion representing a 5.8% year-over-year increase. The company posted earnings per share of $5.15, beating analyst consensus estimates of $4.77 by $0.38. Key financial metrics included a net margin of 20.96% and a return on equity of 137.41%, while the firm provided full-year 2026 guidance ranging between $21.70 and $23.10 per share. Analyst sentiment remains mixed following the earnings release, with Royal Bank of Canada maintaining a positive rating while Wall Street Zen downgraded the stock from buy to hold. Morgan Stanley lowered its price target to $333.00 with an equal weight rating, whereas Guggenheim raised its target to $343.00 but kept a neutral stance. The consensus rating is currently Hold with a price target of $356.62, and insider trading saw SVP Nancy A. Grygiel sell 1,237 shares for approximately $400,454.